BR102018002462A8 - Kit, composição de uso tópico, filme e seus usos - Google Patents

Kit, composição de uso tópico, filme e seus usos

Info

Publication number
BR102018002462A8
BR102018002462A8 BR102018002462A BR102018002462A BR102018002462A8 BR 102018002462 A8 BR102018002462 A8 BR 102018002462A8 BR 102018002462 A BR102018002462 A BR 102018002462A BR 102018002462 A BR102018002462 A BR 102018002462A BR 102018002462 A8 BR102018002462 A8 BR 102018002462A8
Authority
BR
Brazil
Prior art keywords
kit
film
topical use
use composition
treatment
Prior art date
Application number
BR102018002462A
Other languages
English (en)
Other versions
BR102018002462A2 (pt
Inventor
Marie Bianchini Julie
A Capone Kimberly
A Dunn Kelly
Fassih Ali
Miksa Davide
Setiawan Barry
D Southall Michael
A Moreira Liliam
Original Assignee
Currahee Holding Company Inc
Johnson & Johnson Consumer Inc
Chenango Zero Llc
Chenango Two Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Currahee Holding Company Inc, Johnson & Johnson Consumer Inc, Chenango Zero Llc, Chenango Two Llc filed Critical Currahee Holding Company Inc
Publication of BR102018002462A2 publication Critical patent/BR102018002462A2/pt
Publication of BR102018002462A8 publication Critical patent/BR102018002462A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0616—Skin treatment other than tanning
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0624—Apparatus adapted for a specific treatment for eliminating microbes, germs, bacteria on or in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A61N2005/0663—Coloured light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A61N2007/0004—Applications of ultrasound therapy
    • A61N2007/0034—Skin treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A presente invenção fornece composições, métodos e kits para o tratamento de acne e outras doenças de pele influenciadas pela P. acnes, que combina a administração de níveis baixos de pelo me- nos um ácido policarboxílico de C2 a C5 e luz azul na pele que neces- sita de tratamento de tais doenças.
BR102018002462A 2017-02-08 2018-02-06 Kit, composição de uso tópico, filme e seus usos BR102018002462A8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15/427,434 US10596134B2 (en) 2017-02-08 2017-02-08 Compositions and methods for treating skin conditions using light and polycarboxylic acids

Publications (2)

Publication Number Publication Date
BR102018002462A2 BR102018002462A2 (pt) 2018-10-30
BR102018002462A8 true BR102018002462A8 (pt) 2022-07-26

Family

ID=61188686

Family Applications (1)

Application Number Title Priority Date Filing Date
BR102018002462A BR102018002462A8 (pt) 2017-02-08 2018-02-06 Kit, composição de uso tópico, filme e seus usos

Country Status (10)

Country Link
US (2) US10596134B2 (pt)
EP (1) EP3360598B1 (pt)
JP (1) JP7214350B2 (pt)
KR (1) KR102631501B1 (pt)
CN (1) CN108392629B (pt)
AU (1) AU2018200900B2 (pt)
BR (1) BR102018002462A8 (pt)
CA (1) CA2992474A1 (pt)
ES (1) ES2794901T3 (pt)
RU (1) RU2761343C2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596134B2 (en) * 2017-02-08 2020-03-24 Johnson & Johnson Consumer Inc. Compositions and methods for treating skin conditions using light and polycarboxylic acids
US10537534B1 (en) * 2019-06-25 2020-01-21 Johnson & Johnson Consumer Inc. Compositions and methods for treating skin conditions using visible light and resorcinols
CN113905715A (zh) 2019-06-28 2022-01-07 宝洁公司 光增强处理方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6223071B1 (en) 1998-05-01 2001-04-24 Dusa Pharmaceuticals Inc. Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light
SE9801647D0 (sv) * 1998-05-12 1998-05-12 Interhealth Ab Therapeutic composition
AU5884600A (en) * 1999-06-25 2001-01-31 Arch Chemicals, Inc. Topical anti-microbial compositions
US20030009158A1 (en) * 2001-07-09 2003-01-09 Perricone Nicholas V. Skin treatments using blue and violet light
WO2008063441A2 (en) 2006-11-16 2008-05-29 The Procter & Gamble Company Personal care composition
KR20090001013A (ko) * 2007-06-29 2009-01-08 주식회사 웰스킨 인돌-3-알킬카복실산을 함유하는 여드름 치료제 및 피지분비 억제제, 및 이를 포함하는 광역학적 치료용 키트
US8771328B2 (en) 2011-09-08 2014-07-08 La Lumiere Llc Light therapy platform system
US10092770B2 (en) 2011-09-08 2018-10-09 Johnson & Johnson Consumer Inc. Light therapy spot applicator
US9533171B2 (en) 2012-06-15 2017-01-03 L'oreal Method for treating acne
US9408790B2 (en) 2012-12-11 2016-08-09 Elc Management Llc Cosmetic compositions with near infra-red (NIR) light-emitting material and methods therefor
RU2557894C2 (ru) * 2013-10-18 2015-07-27 Общество с ограниченной ответственностью "Фарма Ген" (ООО "Фарма Ген") Косметическое средство для быстрого восстановления кожи
CN105873567A (zh) 2013-12-31 2016-08-17 强生消费者公司 形成一体膜产品的方法
CN105873573B (zh) 2013-12-31 2020-11-24 强生消费者公司 形成成型膜产品的方法
KR102240525B1 (ko) 2013-12-31 2021-04-16 존슨 앤드 존슨 컨수머 인코포레이티드 다층의 형상화된 필름을 형성하기 위한 방법
JP6517216B2 (ja) 2013-12-31 2019-05-22 ジョンソン・アンド・ジョンソン・コンシューマー・インコーポレイテッド 多層賦形フィルム製品を形成するための単一パス方法
US9474699B2 (en) * 2014-03-31 2016-10-25 Johnson & Johnson Consumer Inc. Compostions and methods for enhancing the topical application of a basic benefit agent
JP2018519294A (ja) 2015-06-22 2018-07-19 ジョンソン・アンド・ジョンソン・コンシューマー・インコーポレイテッドＪｏｈｎｓｏｎ ＆ Ｊｏｈｎｓｏｎ Ｃｏｎｓｕｍｅｒ Ｉｎｃ． 皮膚に有益な効果を与えるための多層局所適用物品
US10596134B2 (en) * 2017-02-08 2020-03-24 Johnson & Johnson Consumer Inc. Compositions and methods for treating skin conditions using light and polycarboxylic acids

Also Published As

Publication number Publication date
ES2794901T3 (es) 2020-11-19
US10596134B2 (en) 2020-03-24
RU2018104449A (ru) 2019-08-06
AU2018200900B2 (en) 2023-05-18
CN108392629B (zh) 2022-06-14
KR102631501B1 (ko) 2024-02-01
RU2761343C2 (ru) 2021-12-07
CN108392629A (zh) 2018-08-14
EP3360598B1 (en) 2020-03-25
AU2018200900A1 (en) 2018-08-23
BR102018002462A2 (pt) 2018-10-30
CA2992474A1 (en) 2018-08-08
JP7214350B2 (ja) 2023-01-30
RU2018104449A3 (pt) 2021-06-01
US20180221318A1 (en) 2018-08-09
US10973789B2 (en) 2021-04-13
JP2018127449A (ja) 2018-08-16
KR20180092286A (ko) 2018-08-17
EP3360598A1 (en) 2018-08-15
US20200179318A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
CO2021003036A2 (es) Compuestos de anillo fusionado
CL2021001171A1 (es) Compuestos de anillo fusionado.
CO2018003134A2 (es) Composiciones para el cuidado bucal que comprenden un aminoácido básico, una combinación de fuentes de iones de zinc y un sistema quelante
CO2022010330A2 (es) Dosificación de gamma-hidroxibutirato (ghb)
ECSP19021312A (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad, kits, y métodos
CR20150571A (es) Compuestos y composiciones terapéuticos
CR20180336A (es) Inhibidores de bromodominio bivalentes y usos de los mismos
CL2017003456A1 (es) Metodos para tratar tumores de celulas epitelioides
CL2017002082A1 (es) Nuevas proteínas especificas para pioverdina y pioquelina
BR112019024785A2 (pt) composto de bifenila ou sal do mesmo, composição farmacêutica, agente antineoplásico e uso
BR112016006926A2 (pt) composições compreendendo um conjugado de ácido quínico com ácido cafeico, usos terapêuticos e cosméticos
BR102018002462A8 (pt) Kit, composição de uso tópico, filme e seus usos
CL2019003402A1 (es) Composiciones sólidas para administración oral.
BR112017010495A2 (pt) tratamentos para envenenamento e composições farmacêuticas, sistemas e kits relacionados
CO2018014339A2 (es) Formas sólidas cristalinas de un inhibidor de bet
CL2020002719A1 (es) Moduladores de nlrp3
BR112017003745A2 (pt) inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
CR20180200A (es) Ciano tienotriazolpirazinas y usos de las mismas
CL2020003277A1 (es) Métodos de fabricación de composiciones de aminoácidos
EA201990560A1 (ru) Композиции, содержащие тритерпеноиды, и их применение для лечения оптической нейропатии
CO2022014499A2 (es) Moduladores de nlrp3
BR112018068027A2 (pt) método para tratar câncer em um paciente e composição farmacêutica
CO2020005065A2 (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
GT201700126A (es) Ácidos piridil-cicloalquil-carboxílicos sustituidos composiciones que los contienen y usos de los mismos
CL2020000127A1 (es) Moduladores terapéuticos del modo inverso de la atp sintasa.

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25A Requested transfer of rights approved

Owner name: CHENANGO ZERO LLC (US)

B25A Requested transfer of rights approved

Owner name: CHENANGO TWO LLC (US)

B25A Requested transfer of rights approved

Owner name: CURRAHEE HOLDING COMPANY INC. (US)

B25D Requested change of name of applicant approved

Owner name: JOHNSON AND JOHNSON CONSUMER INC. (US)

B25A Requested transfer of rights approved

Owner name: JOHNSON AND JOHNSON CONSUMER INC. (US)

B25D Requested change of name of applicant approved

Owner name: JOHNSON AND JOHNSON CONSUMER INC. (US)